To further explore the contribution of human memory B cells in ICI treated MM patients and the existence of targeting antibodies as a long-term anti-tumor humoral response, we developed a screening strategy based on BCR repertoire analysis by next generation sequencing (NGS) coupled with ex vivo production of tumor-reactive and tumor-specific antibodies. The gene discussed is BCR; the disease is neoplasm.